Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Array BioPharma
Sponsor:
Information provided by (Responsible Party):
Array BioPharma
ClinicalTrials.gov Identifier:
NCT01649336
First received: July 22, 2012
Last updated: June 23, 2014
Last verified: June 2014

July 22, 2012
June 23, 2014
July 2012
August 2014   (final data collection date for primary outcome measure)
Establish the recommended Phase 2 dose of study drug administered on continuous and intermittent schedules in combination with paclitaxel. [ Time Frame: One year ] [ Designated as safety issue: Yes ]
Establish the recommended Phase 2 dose of study drug in combination with paclitaxel. [ Time Frame: One year ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01649336 on ClinicalTrials.gov Archive Site
  • Characterize the safety profile of the study drug in combination with paclitaxel in terms of adverse events and clinical laboratory tests. [ Time Frame: One year ] [ Designated as safety issue: Yes ]
  • Assess the efficacy of the study drug in combination with paclitaxel in terms of tumor response, duration of response and progression-free survival. [ Time Frame: One year ] [ Designated as safety issue: No ]
  • Assess the potential plasma pharmacokinetic (PK) interactions between study drug, metabolites and paclitaxel in terms of plasma concentrations and noncompartmental PK parameters. [ Time Frame: One year ] [ Designated as safety issue: No ]
  • Assess possible PK/efficacy and PK/safety correlations. [ Time Frame: One year ] [ Designated as safety issue: No ]
  • Assess potential predictive biomarkers of clinical activity for the study drug in combination with paclitaxel. [ Time Frame: One year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Not Provided

This is a Phase 1 study during which patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer will receive investigational study drug MEK162 and paclitaxel. Patients will receive increasing doses of study drug in combination with paclitaxel in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 36 patients from the US will be enrolled in this study.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer
  • Drug: MEK162, MEK inhibitor; oral
    multiple dose, escalating
  • Drug: Paclitaxel, mitotic inhibitor; intravenous
    multiple dose, single schedule
Experimental: MEK162 + paclitaxel
Interventions:
  • Drug: MEK162, MEK inhibitor; oral
  • Drug: Paclitaxel, mitotic inhibitor; intravenous
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
36
Not Provided
August 2014   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Histologically confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal cancer (measurable or evaluable, nonmeasurable disease) that is platinum-resistant or refractory. In the judgment of the Investigator, a patient who is platinum-sensitive but would not benefit from further platinum treatment is also eligible.
  • Must have had ≥ 1 prior platinum-based chemotherapeutic regimen containing carboplatin, cisplatin or another organoplatinum compound for management of primary disease. This initial treatment may have included intraperitoneal (IP) therapy, consolidation, non-cytotoxic agents or extended therapy administered after surgical or non-surgical assessment.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
  • Available archival tumor sample (excisional or core biopsy) that can be acquired and provide consent to biomarker testing of the tumor.
  • Additional criteria exist.

Key Exclusion Criteria:

  • History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
  • Prior therapy with a MEK inhibitor.
  • History of hypersensitivity to taxanes or drug formulations containing Cremophor®.
  • History of acute coronary syndromes.
  • Uncontrolled or symptomatic brain metastases that are not stable, require steroids, are potentially life-threatening or that have required radiation within 28 days prior to first dose of study treatment.
  • Concomitant malignancies or previous malignancies with less than a 5-year disease-free interval at the time of enrollment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or ductal carcinoma in situ may enroll irrespective of the time of diagnosis.
  • Known positive serology for the human immunodeficiency virus (HIV), active hepatitis C, and/or active hepatitis B.
  • Treatment with ritonavir at the time of first dose of study treatment.
  • Treatment with continuous or intermittent small molecular therapeutics, biologic therapy or hormonal therapy within 28 days prior to first dose of study treatment.
  • Treatment with a cyclical chemotherapy within a period of time that is less than the cycle length used for that treatment prior to first dose of study treatment.
  • Treatment with any other investigational agents within a period of time that is less than the cycle length used for the treatment or within 28 days (whichever is shorter) prior to first dose of study treatment.
  • Treatment with prior radiotherapy within 21 days prior to first dose of study treatment; however, if the radiation portal covered ≤ 10% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy.
  • Additional criteria exist.
Female
18 Years and older
No
Contact: Array BioPharma Clinical Trial Call Center 303-381-6604
United States
 
NCT01649336
ARRAY-162-112
No
Array BioPharma
Array BioPharma
Not Provided
Not Provided
Array BioPharma
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP